Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia — Stella

Home/Hematologic Diseases/IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

View on ClinicalTrials.gov

Recruiting

Back to Hematologic Diseases trials

IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang

Key details

Phase

Early testing

Sponsor

Zhejiang University

Enrollment target

~20 participants

Started

November 2025

Primary completion

November 2028

Age range

18 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.